<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480310</url>
  </required_header>
  <id_info>
    <org_study_id>GA27909</org_study_id>
    <nct_id>NCT01480310</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers</brief_title>
  <official_title>A Phase Ia, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase Ia, randomized, double-blind, placebo-controlled, single ascending dose (SAD)
      study in male and female healthy volunteers, aged 18-55 years, enrolled at a single study
      site in Canada.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to approximately 100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: maximum serum concentration (Cmax)</measure>
    <time_frame>up to approximately 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: time to maximum serum concentration (tmax)</measure>
    <time_frame>up to approximately 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: apparent clearance (CL/F)</measure>
    <time_frame>up to approximately 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Terminal half-life (t½)</measure>
    <time_frame>up to approximately 100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCAF5352A</intervention_name>
    <description>may receive up to 3 subcutaneous doses of MCAF5352A</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>may receive up to 3 subcutaneous doses of placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total body weight between 45 and 110 kg

          -  Vital signs within the following ranges: oral body temperature of 35°C to 37.5°C,
             systolic blood pressure of 90 to 140 mmHg, diastolic blood pressure of 50 to 90 mmHg,
             and pulse rate of 45 to 100 bpm

          -  Laboratory test parameters within normal reference ranges of the safety laboratory

          -  Female subjects: Willing to use two effective methods of contraception from screening
             to a minimum of 4 months after the last dose of study drug. Reliable forms of
             contraception include oral hormonal contraceptives, patch hormonal contraceptives,
             vaginal ring, intrauterine device, physical double-barrier methods, surgical
             hysterectomy, or vasectomy by male partner.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Administration of a live, attenuated vaccine within 30 days before Day 1 or
             anticipation that such a live attenuated vaccine will be required within 100 days of
             Day 1

          -  Subjects may receive influenza vaccination only during influenza season (approximately
             October to March). Subjects must not receive live attenuated influenza vaccine within
             30 days prior to Day 1 or at any time during the study.

          -  Any major illness within 30 days prior to Day 1

          -  Clinically significant illness requiring treatment within 14 days prior to Day 1

          -  History of clinically significant ECG abnormalities or a known family history of
             cardiac conduction system disease

          -  Positive test results indicating current or past infection with human immunodeficiency
             virus (HIV-1 or 2), hepatitis B virus (hepatitis B surface antigen [HBsAg], hepatitis
             B core antibody [anti-HBc]), or hepatitis C virus (HCV)

          -  Positive screening test for latent mycobacterial infection within the 2 months
             preceding Day 1 without evidence of a completed course of anti-tubercular therapy or
             previous BCG vaccination

          -  History of significant chronic or recurrent infections

          -  History of clinically significant drug allergy and/or a known hypersensitivity to
             protein therapeutics or formulation components or a related drug

          -  History of alcohol or drug abuse within 12 months prior to Day 1, or evidence of such
             abuse as indicated by the specific screening laboratory tests results, or alcohol
             consumption of more than 14 units of alcohol per week

          -  Positive breathalyzer for alcohol or urine screen results for drugs of abuse, or
             prescription medications

          -  Subjects who have previously received the study drug

          -  Participation in a clinical trial within 4 weeks before Day 1 or use of any
             experimental or biologic therapy within the 12 weeks prior to Day 1 or within 5
             half-lives of the product, whichever is greater

          -  Use of prescription drugs within 14 days prior to Day 1 or during the study, except
             for hormonal contraceptives or hormone replacement therapy

          -  Use of over-the-counter (OTC) medication within 7 days prior to Day 1 or during the
             study. Medications such as acetaminophen and ibuprofen and routinely-taken dietary
             supplements, including vitamins and herbal supplements are allowed at the discretion
             of the investigator and provided that the medication in question has no discernible
             impact on the study.

          -  Donation of plasma within 7 days prior to Day 1. Donation or loss of blood of 50 mL to
             499 mL of blood within 30 days, or more than 499 mL within 56 days prior to Day 1.

          -  Lack of peripheral venous access

          -  Known history of mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

